FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
61 letters match. Newest first.
-
DrugsNatural Essentials, Inc.
FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.
High risk -
DrugsLGM Pharma Solutions, LLC
FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.
High risk -
DrugsConroe Welding Supply, Inc.
FDA warns Conroe Welding Supply over medical oxygen manufacturing failures, including untested batches and a container with 99% (b)(4).
High risk -
DrugsNorthland Nuclear Medicine, LLC
FDA warned Northland Nuclear Medicine in Bismarck, ND, that its PET drugs are adulterated because it failed to investigate microbial contamination and low yields.
High risk -
DrugsRohto Pharmaceutical Co., Ltd.
FDA cites Rohto Vietnam eye-drop plant for falsified sterility records, poor aseptic practices, and unapproved Cooling Eye Drops.
High risk -
DrugsSnugZ USA, Inc.
SnugZ USA, an OTC drug maker in West Jordan, Utah, was cited for releasing drugs after retesting failed batches until they passed.
High risk -
DrugsEurofins SF Analytical Laboratories, Inc.
FDA warned Eurofins SF Analytical Laboratories, a contract drug-testing lab, that it kept incomplete microbial test records and skipped required investigations.
High risk -
DrugsSilgan Dispensing Systems
Silgan Unicep Packaging was cited for manufacturing quality failures and unapproved new drugs after invalidated microbial tests and a fungal recall.
High risk -
DrugsSCA Pharmaceuticals, LLC
SCA Pharmaceuticals' sterile compounded drugs were made under unsanitary conditions with serious manufacturing violations, FDA says.
High risk -
DrugsPine Pharmaceuticals, LLC
FDA cited outsourcing facility Pine Pharmaceuticals in Tonawanda, NY, for insanitary sterile compounding conditions and CGMP failures after a November 2025 inspection.
High risk -
DrugsFresenius Kabi USA LLC
FDA warns Fresenius Kabi USA over manufacturing failures for sterile injectables at Melrose Park, including endotoxin contamination and media fill failures.
High risk -
DrugsCuria New York, Inc.
FDA warned Curia New York's Rensselaer, New York API plant that undocumented lab injections, shredded records and shared passwords violate CGMP.
High risk -
DrugsBentley Laboratories LLC
Bentley Laboratories LLC was cited for CGMP violations and for marketing unapproved acne drugs.
High risk -
BiologicsNexCell Scientific Inc
NexCell Scientific markets an unapproved, unlicensed umbilical cord blood cell product with serious manufacturing violations.
High risk -
DrugsBausch & Lomb Inc.
FDA warns Bausch & Lomb of persistent microbial contamination and poor aseptic controls at its Tampa sterile drug plant.
High risk -
DrugsJabil Inc.
FDA warned Jabil Inc. after an inspection found inadequate investigations of mold and sterility failures at its sterile injectable contract manufacturer.
High risk -
DrugsSuretec Innovations, LLC
Suretec Innovations failed manufacturing quality rules for OTC sanitizing wipes and did not list a private-label wipe.
High risk -
DrugsK.C. Pharmaceuticals, Inc.
FDA cited K.C. Pharmaceuticals of Pomona, CA, for sterile-drug manufacturing failures, including aseptic practice problems and failed media fills.
High risk -
DrugsAuriga Research Pvt. Ltd.
Auriga Research, an Indian contract drug testing lab, failed to keep complete lab records and properly investigate failing test results.
High risk -
DrugsLico Industries, LLC., d.b.a. American Towelette Company
FDA warns Lico Industries (American Towelette) that its OTC drug wipes are adulterated due to poor quality oversight, dirty equipment and falsified records.
High risk -
DrugsIsland Kinetics, Inc. d.b.a. CoValence Laboratories
Island Kinetics (CoValence Laboratories) made OTC acne drugs without process validation and shipped unapproved, misbranded acne products.
High risk -
DrugsBioMylz Pvt. Ltd.
FDA found destroyed records, inadequate process and cleaning validation, missing microbial testing, and incomplete drug listings at BioMylz, an Indian OTC drug manufacturer.
High risk -
DrugsShimoga Chemicals
FDA warns Shimoga Chemicals of manufacturing quality and data integrity failures in clomiphene citrate active ingredient.
High risk -
DrugsSpa De Soleil, Inc.
FDA cites Spa De Soleil for CGMP violations in OTC topical drugs, including water system failures and missing component identity testing.
High risk -
DrugsInternational Medication Systems Limited
FDA found insect larvae and heavy microbial growth in International Medication Systems' sterile filling area; its epinephrine injection lot was later recalled.
High risk -
DrugsExcelvision - Fareva
FDA warned Excelvision-Fareva after a 2026 inspection found inadequate contamination investigations and aseptic failures for sterile drugs.
High risk -
DrugsHuons Co., Ltd.
FDA cites Huons in South Korea for data integrity and sterility failures in drug manufacturing.
High risk -
DrugsJubilant HollisterStier General Partnership
FDA found sterile drug manufacturing and investigation failures at Jubilant HollisterStier in Kirkland.
High risk -
DrugsPharmathen International S.A.
FDA warns Pharmathen over inadequate aseptic controls at its Greek plant making sterile drugs for the U.S.
High risk -
DevicesHappiest Baby, Inc.
FDA says Happiest Baby marketed unapproved SNOO sleep sacks and hospital bundle and mishandled complaints.
High risk -
DrugsMedline Inc
FDA warned Medline Inc about repeated Bacillus cereus contamination in its drug products and inadequate investigations.
High risk -
DrugsLaboratorios Jaloma S.A. de C.V.
FDA found Laboratorios Jaloma’s OTC drug lab records were inaccurate, microbial tests unvalidated, and electronic data missing or uncontrolled.
High risk -
DrugsAlchymars ICM SM Private Limited
FDA found Alchymars API manufacturing had poor equipment and facility maintenance, making its APIs adulterated and prompting an import alert.
High risk -
DrugsMukesh B. Chandre, M.D., MBBS/Ashirwad Hospital & Research Centre
FDA warned clinical investigator Dr. Mukesh Chandre over informed consent failures in a doxorubicin liposome bioequivalence study.
High risk -
DrugsProRx LLC
ProRx LLC, an outsourcing facility, made sterile compounded drugs under insanitary conditions and without required 503B eligibility.
High risk -
DrugsCareFusion 213, LLC
FDA warns CareFusion 213 over inadequate investigations and contamination controls at its El Paso sterile drug plant.
High risk -
DrugsActive Cosmetics Manufacturing Inc.
FDA cited Active Cosmetics Manufacturing for releasing topical OTC drugs after microbial contamination without thorough investigations.
High risk -
DrugsAva Inc.
FDA warned Ava Inc. about adulterated drugs after an inspection found data-integrity failures and hidden trial injections in its Willowbrook, Illinois lab.
High risk -
DrugsLexia LLC
FDA cited Lexia for manufacturing violations in an OTC topical pain relief drug, including missing release and component testing.
High risk -
DrugsIntas Pharmaceuticals Limited
FDA warns Intas Pharmaceuticals' Dehradun, India plant over weak out-of-spec investigations and untracked batch-record edits for its tablets.
High risk -
DrugsPar Health USA, LLC & Endo USA, Inc.
FDA cited Par Health USA/Endo USA’s Rochester plant for sterile injectable contamination-control, media fill, and visual inspection failures after an October 2025 inspection.
High risk -
DrugsUCSF Radiopharmaceutical Facility
FDA cited UCSF Radiopharmaceutical Facility for inadequate sterility failure investigations and environmental monitoring of sterile drug manufacturing.
High risk -
DrugsRC Outsourcing, LLC
FDA warned outsourcing facility RC Outsourcing of Lowellville, Ohio, that its sterile drugs were made under insanitary conditions that risk contamination.
High risk -
DrugsMedical Products Laboratories, Inc.
Medical Products Laboratories was cited for manufacturing failures and selling unapproved prescription skin drugs.
High risk -
DrugsChemco Corporation
FDA warns Chemco Corporation about CGMP failures and unapproved, misbranded OTC drug products from its Miami Lakes facility.
High risk -
DrugsMicrobiological Testing & Consulting, LLC
FDA warned contract testing lab Microbiological Testing & Consulting over CGMP violations in drug product microbiological testing.
High risk -
DrugsOraLabs, Inc.
FDA warned OraLabs, an OTC drugmaker in Parker, Colorado, that it skipped microbial release testing and dismissed contamination findings.
High risk -
DrugsA. Nelson & Co. Ltd.
London homeopathic drug maker A. Nelson & Co. shipped children's products without microbial testing and discarded quality records.
High risk -
DrugsSignature Formulations, LLC
FDA says Signature Formulations made OTC drugs on shared equipment without adequate controls, risking hormone contamination.
High risk -
DrugsBoothwyn Pharmacy, LLC
Boothwyn Pharmacy made sterile drugs in insanitary conditions and shipped lots that failed sterility and potency tests.
High risk